Clinical Trial: TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers, a Phase 0/I Study.

U.S., June 7 -- ClinicalTrials.gov registry received information related to the study (NCT07009184) titled 'TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers, a Phase 0/I Study.' on May 28.

Brief Summary: In recent years, there is increasing interest in antibodies for imaging, antibody-drug conjugates (ADC) and targeted radionuclide therapy (TRT). With these techniques, antibodies are used as a vector to deliver a cytotoxic drug or radionuclide for therapy or nuclear medicine imaging. One such antibody-based vector suitable for delivering a cytotoxic drug or radionuclide is trastuzumab, which targets HER2 that is overexpressed in cancers such as breast, gastric and gastroesophageal junction carcinomas. Unfortunately, antibodies g...